Due to COVID-19, HCA’s lobby is closed until further notice. Learn more about your virtual customer service options.

Distributing opioid overdose reversal medications (2SSB 5195)

2SSB 5195 helps to increase access to naloxone for all individuals at risk of an opioid overdose. The law requires hospital emergency departments (EDs) and many certified and licensed behavioral health settings to distribute prepackaged naloxone to individuals at risk of an opioid overdose.

Education materials

Toolkits

Emergency department (ED)

ED toolkit

SB 5195 Emergency Department implementation toolkit

ED appendices

Appendix A. SB 5195 ED requirement summary
Appendix B. Sample naloxone distribution policy
Appendix C. Sample workflow quick sheet
Appendix D. Sample smart phrases
Appendix E. Sample staff training presentation
Appendix F. Sample staff competency
Appendix G. Sample distribution signature sheet
Appendix H. Administrative FAQ
Appendix I. Clinical staff FAQ
Appendix J. Opioid Overdose Prevention and Directions for Naloxone Use (patient trifold brochure)
- Opioid Overdose Prevention Directions for Naloxone Use (translated in other languages)
Appendix K Patient Education Harm Reduction and MOUD (trifold brochure)
- Patient Education Harm Reduction and MOUD (translated in other languages)
Appendix L. Opioid Overdose Prevention and Directions for Naloxone Use (EHR/AVS version)
Appendix M. Patient Education Harm Reduction and MOUD (EHR/AVS version)

Behavioral health agency (BHA)

BHA Toolkit

SB 5195 Behavioral Health Agency implementation toolkit

BHA appendices

Appendix A. SB 5195 BHA requirement quick sheet
Appendix B. Administrative FAQ
Appendix C. Frontline staff FAQ
Appendix D. Sample workflow
Appendix E. Sample smart phrases
Appendix F. Sample staff training presentation
Appendix G. Sample staff competency sheet
Appendix H. Sample distribution signature sheet
Appendix I. Opioid overdose prevention and directions for naloxone use patient trifold
Appendix J. Patient education trifold harm reduction and MOUD
Appendix K. Opioid overdose prevention and directions for naloxone use patient EHR/AVS version
Appendix L. Patient education harm reduction and MOUD ERH/AVS version

Webinars

HCA Lunch and Learn series for behavioral health agencies (December 8)
- Watch the webinar
- View the slide deck
HCA Lunch and Learn series for behavioral health agencies (December 15)
- Watch the webinar
- View the slide deck

Contact

For training, consultation, educational materials, and implementation questions
Laura Meader, MA, LSWAIC
Overdose reversal medication program director
Email: laura.meader@hca.wa.gov

For billing and pharmacy questions
Email: Applehealthpharmacypolicy@hca.wa.gov